New perspectives in the treatment of hypertension with arterial disease

Norman M Kaplan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The results of large-scale clinical trials of the therapy of mild hypertension have cast some doubts upon the routine use of current approaches in those at relatively low risk. Therefore, we must consider both the relative degree of risk for the individual patient and the potential risks of the therapy to be used. Those patients with preexisting arterial disease are, by nature, at a higher degree of risk. Their arterial disease likely reflects the interactions of multiple risk factors, all of which must be considered. Therefore, they will more likely need active drug therapy as well as multiple changes in diet, physical activity, and other life habits. The degree and nature of preexisting arterial disease may also influence the choice of drug therapy. In particular, further aggravation of hypercholesterolemia and glucose intolerance must be avoided and more careful attention must be given to avoid hypokalemia. The use of β-adrenergic blocking drugs may be particularly well-suited to those with coronary disease although here, too, attention must be given to their potential for elevation of serum triglycerides and decrease in renal blood flow. Newer types of therapy including calcium-entry blockers, converting enzyme inhibitors, and serotonin antagonists will probably be of particular use in such patients.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume7
Issue numberSUPPL. 2
StatePublished - 1985

Fingerprint

Hypertension
Preexisting Condition Coverage
Drug Therapy
Serotonin Antagonists
Glucose Intolerance
Hypokalemia
Renal Circulation
Enzyme Inhibitors
Therapeutics
Hypercholesterolemia
Adrenergic Agents
Habits
Coronary Disease
Triglycerides
Clinical Trials
Exercise
Diet
Calcium
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

New perspectives in the treatment of hypertension with arterial disease. / Kaplan, Norman M.

In: Journal of Cardiovascular Pharmacology, Vol. 7, No. SUPPL. 2, 1985, p. 131-134.

Research output: Contribution to journalArticle

@article{253eaee4812e420e8aa74ebefb75ff6f,
title = "New perspectives in the treatment of hypertension with arterial disease",
abstract = "The results of large-scale clinical trials of the therapy of mild hypertension have cast some doubts upon the routine use of current approaches in those at relatively low risk. Therefore, we must consider both the relative degree of risk for the individual patient and the potential risks of the therapy to be used. Those patients with preexisting arterial disease are, by nature, at a higher degree of risk. Their arterial disease likely reflects the interactions of multiple risk factors, all of which must be considered. Therefore, they will more likely need active drug therapy as well as multiple changes in diet, physical activity, and other life habits. The degree and nature of preexisting arterial disease may also influence the choice of drug therapy. In particular, further aggravation of hypercholesterolemia and glucose intolerance must be avoided and more careful attention must be given to avoid hypokalemia. The use of β-adrenergic blocking drugs may be particularly well-suited to those with coronary disease although here, too, attention must be given to their potential for elevation of serum triglycerides and decrease in renal blood flow. Newer types of therapy including calcium-entry blockers, converting enzyme inhibitors, and serotonin antagonists will probably be of particular use in such patients.",
author = "Kaplan, {Norman M}",
year = "1985",
language = "English (US)",
volume = "7",
pages = "131--134",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - New perspectives in the treatment of hypertension with arterial disease

AU - Kaplan, Norman M

PY - 1985

Y1 - 1985

N2 - The results of large-scale clinical trials of the therapy of mild hypertension have cast some doubts upon the routine use of current approaches in those at relatively low risk. Therefore, we must consider both the relative degree of risk for the individual patient and the potential risks of the therapy to be used. Those patients with preexisting arterial disease are, by nature, at a higher degree of risk. Their arterial disease likely reflects the interactions of multiple risk factors, all of which must be considered. Therefore, they will more likely need active drug therapy as well as multiple changes in diet, physical activity, and other life habits. The degree and nature of preexisting arterial disease may also influence the choice of drug therapy. In particular, further aggravation of hypercholesterolemia and glucose intolerance must be avoided and more careful attention must be given to avoid hypokalemia. The use of β-adrenergic blocking drugs may be particularly well-suited to those with coronary disease although here, too, attention must be given to their potential for elevation of serum triglycerides and decrease in renal blood flow. Newer types of therapy including calcium-entry blockers, converting enzyme inhibitors, and serotonin antagonists will probably be of particular use in such patients.

AB - The results of large-scale clinical trials of the therapy of mild hypertension have cast some doubts upon the routine use of current approaches in those at relatively low risk. Therefore, we must consider both the relative degree of risk for the individual patient and the potential risks of the therapy to be used. Those patients with preexisting arterial disease are, by nature, at a higher degree of risk. Their arterial disease likely reflects the interactions of multiple risk factors, all of which must be considered. Therefore, they will more likely need active drug therapy as well as multiple changes in diet, physical activity, and other life habits. The degree and nature of preexisting arterial disease may also influence the choice of drug therapy. In particular, further aggravation of hypercholesterolemia and glucose intolerance must be avoided and more careful attention must be given to avoid hypokalemia. The use of β-adrenergic blocking drugs may be particularly well-suited to those with coronary disease although here, too, attention must be given to their potential for elevation of serum triglycerides and decrease in renal blood flow. Newer types of therapy including calcium-entry blockers, converting enzyme inhibitors, and serotonin antagonists will probably be of particular use in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0021814776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021814776&partnerID=8YFLogxK

M3 - Article

C2 - 2409362

AN - SCOPUS:0021814776

VL - 7

SP - 131

EP - 134

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 2

ER -